Tg Therapeutics (TGTX) Revenue (2017 - 2026)

Tg Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $204.9 million for Q1 2026.

• In Q1 2026, Revenue rose 69.56% year-over-year to $204.9 million; the TTM figure through Mar 2026 stood at $700.3 million (up 81.26% YoY), while the FY2025 annual figure was $616.3 million, up 87.32% from the prior year.
• Revenue was $204.9 million for Q1 2026 at Tg Therapeutics, up from $192.6 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $204.9 million in Q1 2026 to a low of $80000.0 in Q4 2022.
• Historically, Revenue has averaged $81.6 million across 5 years, with a median of $73.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Revenue sank 96.55% in 2022, then soared 176298.94% in 2023.
• A 5-year view of Revenue shows it stood at $80000.0 in 2022, then surged by 54863.75% to $44.0 million in 2023, then surged by 146.04% to $108.2 million in 2024, then jumped by 78.0% to $192.6 million in 2025, then grew by 6.41% to $204.9 million in 2026.
• The last three Revenue figures came in at $204.9 million (Q1 2026), $192.6 million (Q4 2025), and $161.7 million (Q3 2025), per Business Quant data.